[
ABSTRAKLatar belakang
Diabetes tipe 2 ditandai dengan resistensi dan defisiensi insulin, selain itu seiring dengan
penuaan kejadian resistensi insulin juga semakin meningkat. Pada studi-studi klinis, resistensi
insulin dan diabetes tipe 2 terbukti meningkatkan kejadian sindrom frailty pada usila. Obat
antidiabetik oral metformin telah dikaitkan dengan penghambatan proses penuaan. Namun
demikian, sampai saat ini belum ada data yang menunjukkan manfaat terapi metformin terhadap
kejadian sindrom frailty. Penelitian ini bertujuan untuk melihat apakah ada efek protektif
metformin terhadap sindrom frailty.
Metodologi
Studi ini dilakukan secara kasus kontrol pada subyek berusia ≥60 tahun yang berobat di
poliklinik Geriatri dan Diabetes FKUI-RSCM, bulan Maret-Juni 2013. Diagnosis frailty
dilakukan dengan menggunakan indeks frailty-40 item (FI-40). Analisis statistik dilakukan
dengan metode chi-square untuk analisis bivariat dan regresi logistik untuk analisis multivariat,
semua data disertai dengan interval kepercayaan 95%.
Hasil
Sindrom frailty didapatkan pada 25% (n=59) subyek penelitian, sedangkan pre-frail pada 72%
(n=170) subyek dan sisanya fit. Metformin ditemukan mempunyai hubungan dengan sindrom
frailty pada usila dengan diabetes mellitus tipe 2, yang tetap bermakna setelah dilakukan analisis
multivariat (adjusted OR 0,043; IK 95% 0,019 – 0,099; p<0,001).
ABSTRACTBackground
Type 2 diabetes (T2DM) was characterised with insulin resistance and deficiency, furthermore
with advancing age the was also an increase in insulin resistance. Clinical studies has proven
that insulin resistance and T2DM increase the incidence of frailty syndrome in the elderly. Oral
antidiabetics metformin was associated with the inhibition of aging process. Eventhough, there
was no data that showed the relationship of metformin therapy to frailty syndrome. This study
aimed to explore the possibility of metformin protective effect on frailty syndrome.
Methodology
This was a case control study conducted in subjects ≥60 years old who visited the Geriatrics and
Diabetes outpatient clinic of Cipto Mangunkusumo National Referral Hospital between March
and June 2013. Diagnosis of frailty was established using the FI-40 item criteria. Statistical
analysis was done with chi-square method for bivariate and logistic regression method in
multivariate analysis, all data was accompanied with 95% confidence interval.
Results
Frailty syndrome was found in 25% of subjects (n=59), with median age of 72 years old (SD
6.27) and median of FI-40 item score was 0.18 (SD 0.085). Metformin was found to have a
significant relationship with frailty syndrome in the elderly diabetics, which retained significant
value after multivariate analysis (adjusted OR 0.043; 95% CI 0.019-0.099; p<0.001).
Conclusion
Metformin was shown to have protective effect against frailty syndrome in elderly diabetics.;Background
Type 2 diabetes (T2DM) was characterised with insulin resistance and deficiency, furthermore
with advancing age the was also an increase in insulin resistance. Clinical studies has proven
that insulin resistance and T2DM increase the incidence of frailty syndrome in the elderly. Oral
antidiabetics metformin was associated with the inhibition of aging process. Eventhough, there
was no data that showed the relationship of metformin therapy to frailty syndrome. This study
aimed to explore the possibility of metformin protective effect on frailty syndrome.
Methodology
This was a case control study conducted in subjects ≥60 years old who visited the Geriatrics and
Diabetes outpatient clinic of Cipto Mangunkusumo National Referral Hospital between March
and June 2013. Diagnosis of frailty was established using the FI-40 item criteria. Statistical
analysis was done with chi-square method for bivariate and logistic regression method in
multivariate analysis, all data was accompanied with 95% confidence interval.
Results
Frailty syndrome was found in 25% of subjects (n=59), with median age of 72 years old (SD
6.27) and median of FI-40 item score was 0.18 (SD 0.085). Metformin was found to have a
significant relationship with frailty syndrome in the elderly diabetics, which retained significant
value after multivariate analysis (adjusted OR 0.043; 95% CI 0.019-0.099; p<0.001).
Conclusion
Metformin was shown to have protective effect against frailty syndrome in elderly diabetics., Background
Type 2 diabetes (T2DM) was characterised with insulin resistance and deficiency, furthermore
with advancing age the was also an increase in insulin resistance. Clinical studies has proven
that insulin resistance and T2DM increase the incidence of frailty syndrome in the elderly. Oral
antidiabetics metformin was associated with the inhibition of aging process. Eventhough, there
was no data that showed the relationship of metformin therapy to frailty syndrome. This study
aimed to explore the possibility of metformin protective effect on frailty syndrome.
Methodology
This was a case control study conducted in subjects ≥60 years old who visited the Geriatrics and
Diabetes outpatient clinic of Cipto Mangunkusumo National Referral Hospital between March
and June 2013. Diagnosis of frailty was established using the FI-40 item criteria. Statistical
analysis was done with chi-square method for bivariate and logistic regression method in
multivariate analysis, all data was accompanied with 95% confidence interval.
Results
Frailty syndrome was found in 25% of subjects (n=59), with median age of 72 years old (SD
6.27) and median of FI-40 item score was 0.18 (SD 0.085). Metformin was found to have a
significant relationship with frailty syndrome in the elderly diabetics, which retained significant
value after multivariate analysis (adjusted OR 0.043; 95% CI 0.019-0.099; p<0.001).
Conclusion
Metformin was shown to have protective effect against frailty syndrome in elderly diabetics.]